Top

Published in:

01-05-2018 | Urology - Original Paper

MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma

Authors: Yulian Mytsyk, Victor Dosenko, Yuriy Borys, Askold Kucher, Katarina Gazdikova, Dietrich Busselberg, Martin Caprnda, Peter Kruzliak, Ammad Ahmad Farooqi, Manyuk Lubov

Published in: International Urology and Nephrology | Issue 5/2018

Abstract

Introduction

Currently, there is no accurate diagnostic molecular biomarker for renal cell carcinoma (RCC). The aim of this study was to assess the expression of microRNA-15a (miR-15a) in urine of patients with RCC and to evaluate its potential as a diagnostic molecular biomarker.

Materials and methods

In total, 67 patients with solid renal tumors were enrolled: clear-cell RCC (ccRCC, n = 22), papillary RCC (pRCC, n = 16), chromophobe RCC (chRCC, n = 14), oncocytoma (n = 8), papillary adenoma (n = 2) and angiomyolipoma (n = 5). MiRNA-15a expression levels measurement in urine were performed using qPCR. Urine of 15 healthy volunteers without kidney pathology was used as control.

Results

We observed a difference in mean miR-15a expression values in groups of pre-operative patients with RCC, benign renal tumors and healthy persons (2.50E−01 ± 2.72E−01 vs 1.32E−03 ± 3.90E−03 vs 3.36E−07 ± 1.04E−07 RFU, respectively, p < 0.01). There was no difference in miR-15a expression between ccRCC, pRCC and chRCC (p > 0.05). Direct association between RCC size and miR-15a expression values was obtained (Pearson correlation coefficient—0.873). On the 8th day after nephrectomy, mean expression value in patients with RCC decreased by 99.53% (p < 0.01). MiR-15a expression differentiated RCC from benign renal tumors with 98.1% specificity, 100% sensitivity at a cut-off value of 5.00E−06 RFU, with AUC—0.955.

Conclusions

MiR-15a expression measured in urine may be used as diagnostic molecular biomarker for RCC.

Spek A, Szabados B, Ziegelmüller B, Stief C, D’Anastasi M, Staehler M (2017) Clinical usage of different guidelines in routine management, therapy and follow-up of patients with renal cell cancer in Germany. Urol Int 98:156–161CrossRefPubMed

Kuthi L, Jenei A, Hajdu A, Németh I, Varga Z, Bajory Z, Pajor L, Iványi B (2017) Prognostic factors for renal cell carcinoma subtypes diagnosed according to the 2016 WHO renal tumor classification: a study involving 928 patients. Pathol Oncol Res 23:689–698CrossRefPubMed

Volpe A, Terrone C, Scarpa RM (2009) The current role of percutaneous needle biopsies of renal tumours. Arch Ital Urol Androl 81:107–112PubMed

Menogue SR, O’Brien BA, Brown AL, Cohen RJ (2013) Percutaneous core biopsy of small renal mass lesions: a diagnostic tool to better stratify patients for surgical intervention. BJU Int 111(4 Pt B):E146–E151CrossRefPubMed

Link RE, Bhayani SB, Allaf ME, Varkarakis I, Inagaki T, Rogers C, Su LM, Jarrett TW, Kavoussi LR (2005) Exploring the learning curve, pathological outcomes and perioperative morbidity of laparoscopic partial nephrectomy performed for renal mass. J Urol 173:1690–1694CrossRefPubMed

Fujii Y, Saito K, Iimura Y, Yasuda Y, Koga F, Masuda H, Yonese J, Ishikawa Y, Fukui I, Kihara K (2011) Incidence of benign pathologic lesions at nephrectomy for renal masses presumed to be stage I renal cell carcinoma in Japanese patients: impact of sex, age, and tumor size. ASCO Meet Abstr 29(7_Suppl):374

Sim SH, Messenger MP, Gregory WM, Wind TC, Vasudev NS, Cartledge J, Thompson D, Selby PJ, Banks RE (2012) Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma. Br J Cancer 107:1131–1137CrossRefPubMedPubMedCentral

Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, Kim DW, Deraffele G, Pos Z, Marincola FM, Kaufman HL (2009) Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 27:2645–2652CrossRefPubMedPubMedCentral

Li G, Feng G, Gentil-Perret A, Genin C, Tostain J (2008) Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. J Urol 180:510–513CrossRefPubMed

10.

Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Staehler M, Volpe A, Powles T (2017) Updated European Association of Urology guidelines regarding adjuvant therapy for renal cell carcinoma. Eur Urol 71:719–722CrossRefPubMed

11.

Youssef YM, White NM, Grigull J, Krizova A, Samy C, Mejia-Guerrero S, Evans A, Yousef GM (2011) Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol 59:721–730CrossRefPubMed

12.

Mlcochova H, Hezova R, Meli AC, Slaby O (2015) Urinary microRNAs as a new class of noninvasive biomarkers in oncology, nephrology, and cardiology. Methods Mol Biol 1218:439–463CrossRefPubMed

13.

Chen X, Wang X, Ruan A, Han W, Zhao Y, Lu X, Xiao P, Shi H, Wang R, Chen L, Chen S, Du Q, Yang H, Zhang X (2014) miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression. Clin Cancer Res 20:2617–2630CrossRefPubMed

14.

Vergho D, Kneitz S, Rosenwald A, Scherer C, Spahn M, Burger M, Riedmiller H, Kneitz B (2014) Combination of expression levels of miR-21 and miR-126 is associated with cancer-specific survival in clear-cell renal cell carcinoma. BMC Cancer 14:25CrossRefPubMedPubMedCentral

15.

Teixeira AL, Ferreira M, Silva J, Gomes M, Dias F, Santos JI, Maurício J, Lobo F, Medeiros R (2014) Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients. Tumour Biol 35:4057–4066CrossRefPubMed

16.

Iwamoto H, Kanda Y, Sejima T, Osaki M, Okada F, Takenaka A (2014) Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. Int J Oncol 44:53–58CrossRefPubMed

17.

Terzuoli E, Donnini S, Finetti F, Nesi G, Villari D, Hanaka H, Radmark O, Giachetti A, Ziche M (2016) Linking microsomal prostaglandin E Synthase-1/PGE-2 pathway with miR-15a and -186 expression: novel mechanism of VEGF modulation in prostate cancer. Oncotarget 7:44350–44364CrossRefPubMedPubMedCentral

18.

Zhu K, He Y, Xia C, Yan J, Hou J, Kong D, Yang Y, Zheng G (2016) MicroRNA-15a inhibits proliferation and induces apoptosis in CNE1 nasopharyngeal carcinoma cells. Oncol Res 24:145–151CrossRefPubMed

19.

Shinden Y, Akiyoshi S, Ueo H, Nambara S, Saito T, Komatsu H, Ueda M, Hirata H, Sakimura S, Uchi R, Takano Y, Iguchi T, Eguchi H, Sugimachi K, Kijima Y, Ueo H, Natsugoe S, Mimori K (2015) Diminished expression of MiR-15a is an independent prognostic marker for breast cancer cases. Anticancer Res 35:123–127PubMed

20.

von Brandenstein M, Depping R, Schäfer E, Dienes HP, Fries JW (2011) Protein kinase C α regulates nuclear pri-microRNA 15a release as part of endothelin signaling. Biochim Biophys Acta 1813:1793–1802CrossRef

21.

Schütte U, Bisht S, Heukamp LC, Kebschull M, Florin A, Haarmann J, Hoffmann P, Bendas G, Buettner R, Brossart P, Feldmann G (2014) Hippo signaling mediates proliferation, invasiveness, and metastatic potential of clear cell renal cell carcinoma. Transl Oncol 7:309–321CrossRefPubMedPubMedCentral

22.

Li T, Morgan MJ, Choksi S, Zhang Y, Kim YS, Liu Z (2010) MicroRNAs modulate the noncanonical transcription factor NF-κB pathway by regulating expression of the kinase IKKα during macrophage differentiation. Nat Immunol 11:799–805CrossRefPubMedPubMedCentral

23.

Morais C, Gobe G, Johnson DW, Healy H (2011) The emerging role of nuclear factor kappa B in renal cell carcinoma. Int J Biochem Cell Biol 43:1537–1549CrossRefPubMed

24.

Smith ZL, Pietzak EJ, Meise CK, Van Arsdalen K, Wein AJ, Malkowicz SB, Guzzo TJ (2015) Simplification of the Fuhrman grading system for renal cell carcinoma. Can J Urol 22:8069–8073PubMed

25.

Zhang L, Xu Y, Xue S, Wang X, Dai H, Qian J, Ni Z, Yan Y (2017) Implications of dynamic changes in miR-192 expression in ischemic acute kidney injury. Int Urol Nephrol 49:541–550CrossRefPubMed

26.

Lv CY, Ding WJ, Wang YL, Zhao ZY, Li JH, Chen Y, Lv J (2018) A PEG-based method for the isolation of urinary exosomes and its application in renal fibrosis diagnostics using cargo miR-29c and miR-21 analysis. Int Urol Nephrol 12:1–10. https://doi.org/10.1007/s11255-017-1779-4

27.

Gowrishankar B, Ibragimova I, Zhou Y, Slifker MJ, Devarajan K, Al-Saleem T, Uzzo RG, Cairns P (2014) MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biol Ther 15:329–341CrossRefPubMed

28.

von Brandenstein M, Pandarakalam JJ, Kroon L, Loeser H, Herden J, Braun G, Wendland K, Dienes HP, Engelmann U, Fries JW (2012) MicroRNA 15a, inversely correlated to PKCα, is a potential marker to differentiate between benign and malignant renal tumors in biopsy and urine samples. Am J Pathol 180:1787–1797CrossRef

29.

Cohen EE, Zhu H, Lingen MW, Martin LE, Kuo WL, Choi EA, Kocherginsky M, Parker JS, Chung CH, Rosner MR (2009) A feed forward loop involving protein kinase C alpha and microRNAs regulates tumor cell cycle. Cancer Res 69:65–74CrossRefPubMedPubMedCentral

30.

Gerstung M, Roth T, Dienes HP, Licht C, Fries JW (2007) Endothelin-1 induces NF-kappaB via two independent pathways in human renal tubular epithelial cells. Am J Nephrol 27:294–300CrossRefPubMed

Title: MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma
Authors: Yulian Mytsyk
Victor Dosenko
Yuriy Borys
Askold Kucher
Katarina Gazdikova
Dietrich Busselberg
Martin Caprnda
Peter Kruzliak
Ammad Ahmad Farooqi
Manyuk Lubov
Publication date: 01-05-2018
Publisher: Springer Netherlands
Published in: International Urology and Nephrology / Issue 5/2018
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-018-1841-x

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma

Abstract

Introduction

Materials and methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Introduction

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2018

Comparison of Vela and holmium laser enucleation of the prostate: a retrospective clinical trial with a 12-month follow-up

The impact of exercise on physical function, cardiovascular outcomes and quality of life in chronic kidney disease patients: a systematic review

Chemokine CXCL3 mediates prostate cancer cells proliferation, migration and gene expression changes in an autocrine/paracrine fashion

Prognostic value of cardiovascular calcifications in hemodialysis patients: a longitudinal study

Effect of pregnancy on cooling tone and rhythmic contractions of the rat urinary bladder

Disparities in early mortality among chronic kidney disease patients who transition to peritoneal dialysis and hemodialysis with and without catheters

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page